DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Symbicort Onset of Action 2

Information source: AstraZeneca
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: budesonide/formoterol (Drug); fluticasone/salmeterol (Drug); albuterol (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: AstraZeneca

Official(s) and/or principal investigator(s):
Catherine Bonuccelli, Study Director, Affiliation: AstraZeneca


The purpose of this study is to compare the early onset of effect of Symbicort compared to Advair Diskus and Ventolin in adults with asthma

Clinical Details

Official title: A Randomized, Multicenter, Placebo and Active-controlled, Single-dose, 4-period, Crossover Study to Evaluate the Bronchodilating Effect of SYMBICORT pMDI Versus Advair Diskus and Ventolin HFA.

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Primary outcome: FEV1 3 minutes post dose

Secondary outcome:

12 hour serial FEV1

Patients perception of effect


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- At least 18 years of age

- Diagnosis of asthma and baseline lung function test results as determined by the


- Required and received inhaled corticosteroids within timeframe and doses specified in

the protocol Exclusion Criteria:

- Severe asthma or asthma that is markedly effected by seasonal factors

- Has required and received non-inhaled corticosteroids within the previous 4 weeks,

has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers

Locations and Contacts

Additional Information

Starting date: March 2003
Last updated: January 21, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017